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Introduction
The lymphatic system ensures tissue homeostasis through the 
transport of nutrients and tissue wastes, absorbs lipids from the 
intestinal tract, serves as a conduit for leukocyte trafficking to 
regional lymph nodes, and modulates the immune response.1 
A role for vascular endothelium growth factors (VEGFs) and 
VEGF receptor (VEGFR) tyrosine kinases in the develop-
ment and maintenance of blood and lymphatic vessels has been 
established in a spectrum of genetic mouse models.2 In mammals, 
the lymphatic endothelial system appears to be derived from the 
blood endothelial compartment and lymphatic progenitor cells,1 
whereas most types of leukocytes appear to be dispensable for 
the development of a functional blood and lymphatic vascular 
system.3 However, recent data suggest that postnatal neovascu-
larization is not restricted to angiogenesis (i.e., neovessel forma-
tion within a pre-existing mature vascular network), but also 
involves vasculogenesis, a process requiring the differentiation 
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Bone marrow-derived endothelial progenitor cells (ePcs) infiltrate into sites of neovascularization in adult tissues and 
mature into functional blood endothelial cells (Becs) during a process called vasculogenesis. human marrow-derived 
ePcs have recently been reported to display a mixed myeloid and lymphatic endothelial cell (lec) phenotype during 
inflammation-induced angiogenesis; however, their role in cancer remains poorly understood. We report the in vitro 
differentiation of human cord blood cD133+cD34+ progenitors into podoplanin+ cells expressing both myeloid markers 
(cD11b, cD14) and the canonical lec markers vascular endothelium growth factor receptor 3 (VegFr-3), lymphatic ves-
sel endothelial hyaluronan receptor 1 (lYVe-1), and prospero homeobox 1 (PrOX-1). These podoplanin+ cells displayed 
sprouting behavior comparable to that of lecs in vitro and a dual hemangiogenic and lymphangiogenic activity in vivo 
in an endothelial cell sprouting assay and corneal vascularization assay, respectively. Furthermore, these cells expressed 
vascular endothelium growth factor (VegF) family members a, -c, and -D. Thus, bone-marrow derived ePcs stimulate 
hemangiogenesis and lymphangiogenesis through their ability to differentiate into lecs and to produce angiogenic 
factors. importantly, plasma from patients with breast cancer induced differentiation of cD34+ cord blood progenitors 
into hemangiogenic and lymphangiogenic cD11b+ myeloid cells, whereas plasma from healthy women did not have this 
effect. consistent with these findings, circulating cD11b+ cells from breast cancer patients, but not from healthy women, 
displayed a similar dual angiogenic activity. Taken together, our results show that marrow-derived ePcs become heman-
giogenic and lymphangiogenic upon exposure to cancer plasma. These newly identified functions of bone-marrow 
derived ePcs are expected to influence the diagnosis and treatment of breast cancer.
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of progenitor cells and their participation in the development 
of a de novo vascular network.4,5 Bone marrow-derived cells 
(BMDCs), including endothelial progenitor cells (EPCs), have 
been suggested to contribute to neo-lymphangiogenesis through 
two distinct mechanisms: (1) through their incorporation into 
growing lymphatic vessels in association with vasculogenesis; 
and (2) via the secretion of lymphangiogenic growth factors. In 
mouse experimental models, bone-marrow derived EPCs have 
been reported to display a mixed myeloid/endothelial pheno-
type,3 to produce the lymphangiogenic growth factors VEGF-A, 
VEGF-C, and VEGF-D, and to be involved in the neovascular-
ization of adult tissues.4,5 Consistent with these findings, deple-
tion of BMDC in murine models using Clodrolip (a liposomal 
drug that depletes macrophages) or genetic approaches severely 
impairs lymphatic vessel functions.3,6 In mice, the contribution 
of BMDC to inflammatory lymphangiogenesis has been demon-
strated in response to various environmental stimuli, including 
lipopolysaccharide (LPS) infection,7-9 skin-wounding in diabe-
tes,10 skin homeostasis in hypertension,11 and cancer.12-15 In con-
trast, two studies have demonstrated that lymphatic endothelial 
cells (LECs) arise independently of the myeloid lineage during 
both embryogenesis and tumor-stimulated angiogenesis.16,17
In humans, a contribution of myeloid cells to lymphangiogen-
esis has been experimentally evinced in the context of pathophys-
iologic conditions such as cancer,18,19 kidney transplantation,20 
nematode infection,21 and pulmonary fibrosis.22 Hence, inflam-
mation seems to be a prerequisite for the transdifferentiation of 
myeloid cells into LECs. Human endothelial progenitor cells 
(EPCs) have been isolated from peripheral blood,18,19,23-25 cord 
blood,23,26 fetal liver,24 or bone marrow,24 and found to reside 
within a subset of CD34+CD133+VEGFR3+,24 CD34+CD11b+,26 
or CD14+/CD34low25 cells. To date, EPCs have been identified 
on the basis of their proliferative potential and the phenotype of 
their progeny,18,24-26 rather than by their vasculogenic potential.26 
Moreover, to our knowledge, the lymphvasculogenic potential 
of human myeloid progenitors has not yet been demonstrated, 
although it has been suggested. Indeed, there is evidence for the 
incorporation of macrophages expressing LEC markers into the 
lymphatic vasculature of inflamed tissues20,21 and the formation 
in vitro of lymphatic-like vessels induced by CD11b+ macrophages 
isolated from patients with pulmonary fibrosis.22 Furthermore, 
correlations have been reported between lymph node metasta-
sis and the frequency of circulating bone marrow-derived EPCs 
in small cell lung cancer19 and the density of tumor-associated 
macrophages expressing VEGFR-3, VEGF-C, and VEGF-D in 
cervical squamous carcinoma.18
Herein, we report the dual hemangiogenic and lymphangio-
genic activity of myeloid CD11b+ podoplanin+ cells differentiated 
in vitro from CD133+CD34+ human cord blood progenitors after 
15 d of exposure to a cocktail of interleukin-6 (IL-6), thrombopoi-
etin, stem cell factor/KIT ligand (SCF/KITL), Fms-related tyro-
sine kinase 3 (FLT-3) ligand, and human plasma. Importantly, 
both hemangiogenic and lymphangiogenic activities of these 
CD11b+podoplanin+ cells dramatically increased during differen-
tiation in the presence of plasma from breast cancer patients com-
pared with plasma from healthy women. In vitro differentiated 
CD11b+ podoplanin+ cells expressed both myeloid markers and 
the canonical LEC markers VEGFR-3, lymphatic vessel endothe-
lial hyaluronan receptor 1 (LYVE-1), and prospero homeobox 1 
(PROX-1). In response to VEGF, podoplanin+ cells proliferated 
and formed sprouts in vitro. Furthermore, CD11b+ podoplanin+ 
cells induced the growth of blood and lymphatic vessels in the 
cornea of immunocompromised mice and consistently produced 
VEGF-A, -C, and -D. Thus, our data show that human bone 
marrow-derived EPCs contribute to lymphangiogenesis through 
differentiation into LECs and secretion of VEGFs.
Results
Breast cancer patient plasma promotes differentiation 
of CD34+ progenitor cells into hemangiogenic and lymphan-
giogenic CD11b+ cells in vitro
We have previously reported that conditioned media of human 
breast cancer cell lines induces the commitment of CD34+ pro-
genitors into hemangiogenic CD11b+ cells in a placenta growth 
factor (PLGF)-dependent manner.26 Here, we examined the 
contribution of plasma from breast cancer patients to the dif-
ferentiation of CD34+ progenitors into hemangiogenic and lym-
phangiogenic CD11b+ cells. To this end, we isolated CD34+ cells 
from human cord blood (purity >95%, Fig. S1) and cultured 
them in the presence of IL-6, thrombopoietin, SCF, and FLT-3 
ligand to achieve continuous production of hematopoietic pro-
genitor cells.27,28 Additionally, we supplemented the culture with 
10% plasma isolated from the peripheral blood of either healthy 
women or untreated breast cancer patients. Ten days later, the 
resultant CD11b+ cells (differentiated from CD34+ progenitors) 
were purified from the culture by positive immunomagnetic 
selection and assessed according to their hemangiogenic and 
lymphangiogenic activities via their ability to induce sprouting 
of human umbilical vein endothelial cells (HUVECs) and LECs 
grown in vitro on microcarrier beads embedded in a 3D fibrin 
gel. CD11b+ cells that differentiated in the presence of plasma 
from breast cancer patients induced dramatic sprouting of 
human HUVECs and LECs as compared with their counterparts 
differentiated in the presence of plasma from healthy women 
(Fig. 1A). Consistent with these findings, CD11b+ cells isolated 
from the peripheral blood of breast cancer patients showed much 
stronger hemangiogenic and lymphangiogenic activities than 
those isolated from the blood of healthy women (Fig. 1B).
In vitro differentiation of podoplanin+ cells from cord blood 
CD34+ progenitors
Differentiation of CD34+ progenitors into angiogenic CD11b+ 
cells was induced by plasma from healthy individuals after a long 
exposure time of 20 d (Fig. 1C). However, plasma from breast 
cancer patients increased both the kinetics of differentiation of 
CD34+ progenitors into angiogenic CD11b+ cells (Fig. 1C) and 
the angiogenic potential of these cells (Fig. 1A and C).
These observations suggest that under the culture conditions 
used in this experiment, BMDCs stimulate hemangiogenesis 
and lymphangiogenesis through their ability to differentiate into 
endothelial cells and/or by providing a source of pro-angiogenic 
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factors. To address these hypotheses, we performed longitudi-
nal monitoring of the cell phenotype over 35 d of culture. First, 
using flow cytometry we examined the expression of neuropi-
lin-1 and 2, which function in angiogenesis as co-receptors 
stabilizing the VEGF/VEGFR complex.2 At day 0, all CD34+ 
cord blood progenitors expressed CD45, but not the VEGF co-
receptor neuropilin-1. A small but detectable fraction of CD34+ 
cells (≤5%) expressed the stem cell marker CD133 as well as 
neuropilin-2 and VEGFR-3 (Fig. S1), consistent with a previous 
report.24 After 10 d in culture, a fraction of the purified CD34+ 
cord blood progenitors had differentiated into a population of 
adherent podoplanin+ cells (Fig. 1D) that persisted, matured, 
and expanded over a 5-wk period. After 3 wk in culture, these 
podoplanin+ cells were detectable in all experiments with an aver-
age frequency of 10.75% ± 6.95% (range 5–23%, n = 10). At 
day 20 to 35, the podoplanin+ cells consisted of two populations 
according to CD31 expression (Fig. 2A). The podoplanin+CD31− 
population was predominantly CD34low and CD45low, whereas 
the podoplanin+CD31+ subset expressed intermediate levels of 
these markers and retained 19% CD34+ progenitor cells. The 
culture also contained a large proportion of podoplanin+CD31+ 
cells that heterogeneously expressed CD34 and CD45 (Fig. 2A). 
Finally, differentiation of CD34+ cord blood progenitor cells into 
podoplanin+ cells was not significantly enhanced by growing 
the cells on surfaces coated with collagen, gelatin, or fibronec-
tin, displaying an average increase in podoplanin+ cell frequency 
relative to the untreated surface of 0–12% ± 4%, P > 0.05, n = 
4). CD31+podoplanin− cell populations that express CD34 but 
not CD45 may be mature endothelial cells whereas their CD34− 
counterparts are likely to be fibroblasts (Fig. 2A).29 Moreover, 
CD31+podoplanin−CD34−CD45+ cells are candidate myeloid 
cells because a fraction of them express CD11b.29
At days 20 to 35, a subset of the podoplanin+ cells (6.5%) co-
expressed neuropilin-1 but not CD133, whereas CD133 progeni-
tors represented more than 15% of cells in the culture (Fig. 2B). 
A vast majority of the CD133+ progenitor cells was podoplanin− 
and neuropilin-1− (>85%, Fig. 2B). To assess whether these 
progenitor cells had matured into podoplanin+ cells, we isolated 
CD133+ cells from a 20-d-old culture by immunomagnetic selec-
tion, stained them with carboxyfluorescein diacetate succin-
imidyl ester (CFSE), and returned them to the original culture. 
Over the first 4 d, the CD133 progenitor cells differentiated into 
podoplanin+ cells and expanded more than 16-fold (Fig. S2) 
indicating that in our cell culture system, and similar to other 
Figure 1. increased hemangiogenic and lymphangiogenic activities of cD11b+ cells differentiated in vitro from cD34+ progenitors in the presence of 
plasma from breast cancer patients. (A–D) The hemangiogenic and lymphangiogenic activities of cD11b+ cells were assessed in vitro by measuring their 
ability to induce sprouting of human umbilical vein endothelial cells (hUVecs) and lymphatic endothelial cells (lecs) grown on microcarrier beads and 
embedded in a 3D fibrin gel. (A) cumulative sprout length for hUVec and lec beads following exposure for 10 d to purified cD11b+ cells differentiated 
in vitro from cD34+ progenitors in the presence of plasma from healthy (h) individuals or breast cancer (Bc) patients (n = 10–12). (B) cumulative sprout 
length for cD11b+ cells isolated from peripheral blood of healthy individuals (h) and breast cancer patients (Bc). (C–D) cD11b+ cells were differentiated 
in vitro from cD34+ progenitors following exposure to healthy plasma and the kinetics of hemangiogenic and lymphangiogenic activities (C) or dif-
ferentiation into podoplanin+ cells (D) were measured. Background sprouting measured with coated hUVec and lec beads alone is shown (none). Data 
in (C) show cumulated sprout length normalized to that measured in the absence of bone marrow-derived cells (BMDcs) and in the presence of 50 ng/
ml VegF-a. statistical significance was determined by student’s t test and differences are indicated for all panels (*P < 0.05; **P < 0.005; ***P < 0.001).
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reports,24,26 EPCs reside within the subset of CD34+CD133+ cells. 
Furthermore, this cell culture system allows continuous in vitro 
maintenance and renewal of a significant proportion (>10%) of 
CD34+ progenitors for over a year,28,30 as well as sustained differ-
entiation of podoplanin+ cells from CD34+ progenitors over sev-
eral months (Fig. 2). Interestingly, the podoplanin+ cells retained 
a significant fraction (approximately 20%) of CD34+ progenitor 
cells (Fig. 2A).
Angiogenic CD11b+ cells from the peripheral blood of can-
cer patients showed reduced expression levels of CD31, podo-
planin, and neuropilin-1 and 2 relative to podoplanin+ cells 
differentiated in vitro. A significant increase in the frequency of 
CD11b+CD14+neuropilin+ cells was observed in the peripheral 
blood of breast cancer patients relative to blood from healthy 
donors (31% ± 13 vs. 15% ± 6, P < 0.05).
In vitro differentiated podoplanin+ cells express markers 
of myeloid and lymphatic endothelial cells
The expression of LECs and myeloid cell markers was exam-
ined by both flow cytometry and confocal microscopy 22 to 
35 d after isolation of the CD34+ precursors from cord blood. 
Although VEGFR-1 is known to be involved in hemangiogen-
esis,2 VEGFR-3, a receptor for VEGF-C and VEGF-D, has been 
shown to be required for LEC function and lymphatic develop-
ment.1 Similarly, VEGFR-2 has been implicated in lymphan-
giogenesis, possibly through binding of VEGF-A, C, and D. 
VEGFR-3, neuropilin-2, the transcription factor PROX-1, and 
Figure 2. in vitro differentiation of cD34+ cord blood precursors into podoplanin+ cells. (A–B) cD34+ hematopoietic progenitors from cord blood were 
isolated by immunomagnetic selection and cultured in vitro. resultant cells were characterized by immunostaining and cytofluorimetric analysis 15 to 
35 d after the isolation of cD34+ cord blood precursors. representative flow cytometry dot plots of the expression profiles of podoplanin, cD31, cD34, 
and cD45 (panel A) and podoplanin, cD133, and neuropilin-1 (panel B) are shown from 10 distinct cultures.
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podoplanin serve as LEC signature markers because their genetic 
deletion in mice has been shown to compromise the development 
of the lymphatic system.1 However, despite the predominant and 
continuous expression of podoplanin in LECs and absence in 
blood endothelial cells (BECs), podoplanin is diversely expressed 
in a broad range of other cell types. Similarly, LYVE-1 has been 
identified as a LEC marker, but is also reportedly expressed in 
activated tissue macrophages.1 We observed that podoplanin+ 
cells differentiated in vitro from CD34+ cord blood progeni-
tors expressed VEGFR-1, VEGFR-2, neuropilin-1, and the LEC 
markers VEGFR-3, neuropilin-2, and LYVE-1 (Fig. 3A). In con-
trast, podoplanin− cells exhibited weaker (VEGFR-1, VEGFR-
2, neuropilin-1) or undetectable (VEGFR-3, neuropilin-2, and 
LYVE-1) expression of these markers (Fig. 3A). In contrast to 
podoplanin− cells, podoplanin+ cells showed elevated expres-
sion of VE-cadherin, a marker of blood endothelial cells (BEC) 
and LECs (Fig. 3A). PROX-1 activity is required not only for 
LEC specification but also to maintain the mature differenti-
ated LEC fate.31-35 Therefore, as shown in Figure 3B, we used 
confocal microscopy to examine PROX-1 and found that most 
(>80%) of the podoplanin+ cells displayed intermediate PROX-1 
expression levels relative to HUVECs (negative) and LECs 
(high). In addition, we compared the expression of CD31 and 
canonical lymphatic markers in HUVECs, mature LECs, and 
podoplanin+ cells by flow cytometry. Podoplanin and neuropi-
lin-2 were expressed by both podoplanin+ cells and LECs, but 
not by HUVECs (Table 1). Podoplanin+ cells displayed inter-
mediate expression levels of LYVE-1 and VEGFR-3 relative to 
Figure 3. in vitro differentiated podoplanin+ cells display markers of lymphatic endothelial cells and myeloid cells. (A–C) cD34+ hematopoietic progeni-
tors from cord blood were isolated by immunomagnetic selection and cultured in vitro. expression of the lymphatic endothelial cell (lec) markers vas-
cular endothelium growth factor receptors (VegFrs), neuropilins, prospero-related homeobox 1 (PrOX-1), and lymphatic vessel endothelial hyaluronan 
receptor 1 (lYVe-1) and of Ve-cadherin was assessed by immunostaining and fluorescence cytometry (A) and confocal microscopy (B) in podoplanin+ 
and podoplanin− cell populations. a. Flow cytometry histograms of the expression level of the indicated marker in each of the two cell types, with filled 
histograms depicting labeling with isotype control antibodies. (B) all podoplanin+ cells (arrows) expressed lYVe-1 and most (> 80%) showed intermedi-
ate PrOX-1 expression relative to human umbilical vein endothelial cells (hUVecs) and human dermal lymphatic microvascular endothelial cells (Dlecs). 
(C) Podoplanin+ cells expression of the myeloid cell markers cD11b and cD14. representative images from three to five experiments are shown. cell 
characterizations were performed in 22- to 35-d-old cultures. Bar, 25 µm.
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HUVECs and LECs, and heterogeneous expression of CD31 
(Table 1). Taken together, these results indicate that podoplanin+ 
cells display a phenotype of maturing LECs. In addition, in 
contrast to HUVECs and LECs, most of the podoplanin+ cells 
expressed CD11b, consistent with their myeloid origin (Fig. 3C). 
Approximately 30% of podoplanin+CD11b+ cells expressed the 
lipopolysaccharide receptor CD14, but not CD11c, indicating 
that this cell population encompassed a monocytic cell subset 
(Fig. 3C). Finally, the presence of hematopoietic progenitors was 
examined by a methylcellulose-based colony assay (StemCell 
Technologies, Inc.). In contrast to podoplanin− cells, podo-
planin+ cells could not form colonies consistent with the expres-
sion of a maturing LEC phenotype (data not shown).
Podoplanin+ cells and mature LECs display a comparable 
aptitude to form sprouts in vitro in response to VEGF
We observed that podoplanin+ cells expanded in response to 
VEGF stimulation (Fig. S3A) and showed a transient increase 
in surface expression of neuropilin-1 and continuous increase in 
expression of podoplanin (Fig. S3B and C). We next examined 
the ability of podoplanin+ cells to form sprouts in response to 
VEGF treatment. Podoplanin+ cells that were positively selected 
from 25-d-old cultures were grown on collagen-coated microcar-
rier beads and embedded in a 3D fibrin gel. We observed that 
podoplanin+ cells adhered weakly to collagen microcarrier beads 
compared with HUVECs and LECs and failed to form the cohe-
sive spheroids in methylcellulose that are usually generated in a 
spheroid sprouting assay. Nevertheless, in response to VEGF-A 
and -C podoplanin+ cells formed sprouts (Fig. 4A) composed of 
cells expressing podoplanin, VEGFR-3, and CD31 (Fig. 4B). 
However, the weak adhesion of podoplanin+ cells to the micro-
carrier beads precluded accurate quantification of the sprout-
ing of podoplanin+ cells and prompted us to generate chimeric 
HUVEC/podoplanin+ cells or LEC/podoplanin+ cell beads that 
showed sustained and reproducible coverage. Sprouts emerging 
from HUVEC, LEC, or podoplanin+ cells were identified by 
incorporation of CFSE in one of the cell types before beading. 
We observed that CFSE incorporation had a weak effect on the 
sprouting ability of endothelial cells of lymphatic origin but a 
moderate effect on those of blood origin, therefore CFSE was 
preferentially used to label the lymphatic cells.
Beads covered exclusively with HUVECs showed strong and 
weak sprouting capacity in response to VEGF-A and VEGF-C, 
respectively. Beads covered exclusively with LEC showed a 
clear opposite trend (Fig. 4C). A combination of VEGF-A and 
VEGF-C had a significant synergistic effect on the sprouting 
capacity of both HUVECs and LECs, with a much stronger effect 
on LECs (Fig. 4C). These differences tended to be much less pro-
nounced on chimeric HUVEC/LEC beads (Fig. 4D), suggesting 
that HUVECs and LECs influence each other. More specifically, 
LECs displayed a highly variable response to VEGF-A on chime-
ric HUVEC/LEC beads (compare panels C and D). Compared 
with LECs, podoplanin+ cells showed similar responsiveness to 
VEGF-A and VEGF-C when mixed with HUVECs on beads 
(compare panels D and E). Furthermore, in chimeric LEC/podo-
planin+ cell beads, podoplanin+ cells and LECs showed compara-
ble responses to VEGF treatment (Fig. 4F). Thus, a hallmark of 
lymphatic cells (i.e., LECs and podoplanin+ cells) is a robust syn-
ergistic stimulatory effect of combined VEGF-A and VEGF-C 
on their sprouting capacity (Fig. 4C and F). Finally, comparable 
results were obtained using CD11b+ positively selected cells (data 
not shown).
In vitro differentiated podoplanin+ cells are lymphangiogenic
Like BMDCs, podoplanin+ cells share markers with both 
LECs and myeloid cells (Fig. 3). Because some mouse BMDCs 
have been reported to contribute to lymphangiogenesis,14 we 
compared the angiogenic potential of podoplanin+ cells and 
mature LECs. To this end, we applied podoplanin+ cells or LECs 
to microcarrier beads that were coated with LECs or HUVECs 
and embedded in a 3D fibrin gel. Podoplanin+ cells induced 
robust sprouting of HUVEC and LEC cells, whereas LECs failed 
to do so (Fig. 5A). These results indicate that, in contrast to 
LECs, podoplanin+ cells are both hemangiogenic and lymphan-
giogenic in vitro. Moreover, the hemangiogenic and lymphangio-
genic activities showed a 6.5-fold enrichment in the podoplanin+ 
cell fraction relative to the podoplanin− cell fraction. We further 
examined the angiogenic activity of podoplanin+ cells by inject-
ing them into the cornea of mice. The cornea is avascular and 
any growth of new vessels from the peripheral limbal vasculature 
reflects angiogenic activity of the injected podoplanin+ cells.36 
Podoplanin+ cells induced the growth of blood and lymphatic 
vessels in the cornea from pre-existing limbal BECs and LECs, 
as shown by CD31 and LYVE-1 immunostaining of sagittal 
sections of the eyes after 30 d (Fig. 5B, arrow heads). Taken 
together these results indicate that, like BMDCs and in contrast 
Table 1. expression of lec markers (lYVe-1, podoplanin, and VegFr-3), cD31, and neuropilin-2 on the surface of hUVecs, Dlecs, and in vitro differenti-
ated podoplanin+ cells
CD31 LYVE-1 Neuropilin-2 Podoplanin VEGFR-3
hUVec 4380 200 13 36 830
Dlec 6858 748 729 47 000 17 231
culture 1 Podo+ cells 3200 458 500 500 4317
culture 2 Podo+ cells 4079 386 610 157 6450
culture 3 Podo+ cells 7043 1007 528 243 3613
Data shown are the mean fluorescence intensity determined by cytofluorimetric analysis, corrected for background staining. expression was measured 
in the podoplanin+ (Podo+) cell fraction of three distinct differentiated cultures (1–3). Dlec, dermal lymphatic endothelial cell; lec, lymphatic endothelial 
cell; hUVec, human umbilical vein endothelial cell; lYVe-1, lymphatic vessel endothelial hyaluronan receptor 1; VegFr, vascular endothelium growth 
factor receptor.
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to mature LECs, podoplanin+ cells enable both hemangiogenesis 
and lymphangiogenesis in vivo. Consistent with these findings, 
we observed that podoplanin+ cells expressed VEGF-A and -C by 
confocal microscopy (Fig. 5C).
Discussion
In the present study we report that human CD34+CD133+ 
bone-marrow derived EPCs possess the ability to differentiate in 
vitro into myeloid LECs expressing VEGF-A, -C, and -D that 
consistently display hemangiogenic and lymphangiogenic activi-
ties. Our findings are consistent with other in vitro studies that 
identified EPCs within CD34+ populations of various origins.21-24 
Nevertheless, although two of these studies reported that BECs 
derived from CD34+ cells formed capillary-like structures after 
plating in Matrigel,21,24 only one reported the differentiation of 
human CD34+ progenitors into ECs expressing VE-cadherin, 
CD51/61, CD105, LYVE-1, and podoplanin.22 However, in 
these studies, authors did not examine the function of these cells 
or expression of PROX-1, a binary switch whose expression is 
constantly required to maintain a LEC fate.31-35
Here, we report that in vitro differentiated podoplanin+ cells 
expressed PROX-1, proliferated, and formed sprouts in response 
to VEGF-C stimulation. Additionally, we show that a strong syn-
ergistic effect of VEGF-A and -C is a common feature of the 
sprouting behavior of these in vitro-derived podoplanin+ cells 
and mature LECs. Relative to HUVECs and mature LECs, 
podoplanin+ cells displayed a decreased aptitude to adhere to 
extracellular matrix components such as collagen microcarrier 
beads. However, similar to mature LECs and in marked contrast 
to HUVECs, podoplanin+ cells failed to form cohesive spheroids 
in vitro. Furthermore, consistent with their CD45 intermediate 
hematopoietic phenotype, podoplanin+ cells remained impaired 
in their ability to form colonies compared with podoplanin− cells, 
but expanded 16-fold from the initial CD133+ precursors over 4 d 
of culture. Hence, CD34+CD133+ cells could be viewed as bone 
marrow-derived EPCs and podoplanin+ cells as BMDCs that 
Figure 4. Podoplanin+ cells and lecs show similar abilities to form sprouts in vitro in response to vascular endothelium growth factor (VegF). in vitro 
sprouting of endothelial cells cultured 25 d using podoplanin+ cells positively selected using anti–podoplanin-Pe antibody and immunomagnetic sepa-
ration. Podoplanin+ cells were labeled with carboxyfluorescein diacetate succinimidyl ester (csFe) and cultured on collagen-coated microcarrier beads 
embedded in a 3D fibrin gel, as described below. (A) epifluorescence microscopy image of cFse-labeled sprouts (dashed line) of podoplanin+ cells 
after 5 d of stimulation with vascular endothelium growth factor (VegF)-a and -c. (B) confocal microscopy images of sprouts of podoplanin+ cells in 
3D fibrin gel 3 d post-stimulation. green, cD31; blue, podoplanin; red, VegF receptor (VegFr). Bar, 75 µm. (C–F) sprouting capacity of endothelial cells 
in response to VegF was evaluated in vitro by measuring the mean cumulative sprout length. (C) Beads were coated exclusively with human umbilical 
vein endothelial cells (hUVecs) or lymphatic microvascular endothelial cells (lecs) (D–F) chimeric beads were coated with both hUVecs and lecs (D), 
hUVec and podoplanin+ cells (E), or lecs and podoplanin+ cells in a 2:1 ratio (F). sprouts of lymphatic origin were identified by incorporation of cFse 
into lecs or podoplanin+ cells. cumulative data from a minimum of three experiments are shown. Background sprouting (96.8 ± 60 pixels) measured 
with coated beads alone was subtracted from all data. significant differences between cell types in response to the same treatment were measured 
by student’s t test; *P < 0.05 in panels C–F; in panel C, significant differences among the treatments for hUVecs and lecs are indicated by blue and red 
asterisks, respectively.
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have acquired a LEC-like phenotype in vitro (refer to Fig. 3). 
This plasticity is not surprising given that EC and BMDC cells 
have been previously shown to exhibit relatively fluid cell fates.37 
Finally, in marked contrast to mature LECs, podoplanin+ cells 
displayed hemangiogenic and lymphangiogenic activities (refer 
to Fig. 5), suggesting that these functions might be specific to 
BMDCs. Although we observed that podoplanin+ cells can insert 
into LEC sprouts, this insertion did not seem to be linked to their 
lymphangiogenic activity because sprouting was also observed in 
the absence of insertion.
Importantly, the dual hemangiogenic and lymphangiogenic 
activity of myeloid cells was enhanced by plasma from breast can-
cer patients. It is unclear why the BMDC and LEC phenotypes 
are so closely related. However, in settings of tumor-induced lym-
phangiogenesis the frequency of CD34+ bone-marrow derived 
EPCs expressing VEGFR-3 was found to be increased in patients 
with small cell lung cancer correlating with lymph node metas-
tasis and poor survival.17 Moreover, the density of macrophages 
expressing VEGF-C and -D was shown to correlate with lymph 
node metastasis in cervical cancer patients.16 These observations 
are particularly relevant in solid cancers, such as breast cancer 
and melanoma, since 80% of metastatic cells are known to dis-
seminate through the lymphatic system38 and their detection 
in regional lymph nodes is an excellent prognostic indicator.39 
Hence, while the role of BMDC in lymphangiogenesis within 
human breast tumors remains poorly understood, the observation 
Figure 5. Podoplanin+ cells are hemangiogenic and lymphangiogenic in vitro and in vivo. The hemangiogenic and lymphangiogenic activities of podo-
planin+ cells (derived from cultured cord blood cD34+ precursor cells) and microvascular lymphatic endothelial cells (lecs) were assessed in vitro by 
measuring their aptitude to induce sprouting of human umbilical vein endothelial cells (hUVecs) and lecs grown on microcarrier beads and embed-
ded in a 3D fibrin gel. (A) cumulated sprout length for hUVec (left panel) and lec (right panel) beads following exposure to podoplanin+ cells or 
lecs. Background sprouting (71.4 ± 57 pixels) measured with hUVec and lec beads alone was subtracted. significant differences were determined by 
student’s t test, *P < 0.05; **P < 0.005). (B) corneal vascularization assay to assess the in vivo hemangiogenic and lymphangiogenic activity of podo-
planin+ cells was performed by transplantation of 30 000 podoplanin+ cells into the corneal stroma of anesthetized nOD-sciD/il2rγnull mice. Fluorescent 
microscopy images of sagittal sections of mouse eyes using antibodies specific for cD31 and lymphatic vessel endothelial hyaluronan receptor 1 (lYVe-
1) revealed de novo formation of blood and lymphatic vessels emerging from the peripheral limbal vasculature (arrow heads) and expanding into the 
cornea (vertical double-headed arrow). single arrow depicts the iris. Bar, 100 μm. cumulative data of three independent experiments are shown in (A) 
and a representative experiment among three is shown in (B). (C) expression of vascular endothelium growth factor (VegF)-a and -c in the podoplanin+ 
cell fraction detected by confocal microscopy. Bar, 12 µm.
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that lymphangiogenesis within the sentinel lymph node precedes 
the arrival of metastatic cells39,40 is highly suggestive of a contri-
bution of lymphangiogenic BMDCs to lymph node metastatic 
spread in breast cancer.
Taken together, our results suggest a plausible mechanism 
accounting for the apparent contribution of marrow-derived 
EPCs and BMDCs to human breast cancer angiogenesis in 
which soluble plasma factors induce the differentiation of bone 
marrow-derived EPCs into hemangiogenic and lymphangio-
genic CD11b+ BMDCs. In the case of breast cancer, our data 
indicate that this differentiation occurs before BMDCs reach 
the tumor microenvironment and most likely while they are 
residing in the bone marrow where CD34+ progenitor cells are 
exposed to unknown plasma factors. Identification of these 
factors is currently underway using the cell culture systems 
described in this study. Delineation of the altered signals and 
pathways driving the differentiation of bone marrow-derived 
EPC into hemangiogenic and lymphangiogenic BMDCs is 
expected to have a critical impact on the diagnosis and treat-
ment of breast cancer.
Materials and Methods
Cells and tissue specimens
Human umbilical vein endothelial cells (HUVECs) and 
adult human dermal lymphatic microvascular endothelial cells 
(DLECs) were >90% pure and were purchased from Lonza. 
Cord blood, peripheral blood, and plasma were obtained accord-
ing to the Declaration of Helsinki and upon written informed 
consent. This study was approved by the ethics committee of 
the University Hospital of Lausanne. Breast cancer patients 
were diagnosed with primary invasive breast carcinoma (T1-
T2 < 3 cm, positive lymph node status for 25% of the patients, 
Grade I-III)41 and untreated.
Confocal microscopy
Cells were processed by cytospin or adhered to Cell-Tak 
coated slides (BD Biosciences, hereafter referred to as BD), fixed 
with 10% formalin for 10 min at 4 °C, permeabilized for 20 min 
at RT with PBS containing 0.05% Triton X-100 and blocked for 
40 min with PBS containing 1% bovine serum albumin (BSA) 
and 5% fetal bovine serum (FBS). Slides were incubated with 
primary antibodies for 20 h at 4 °C, washed, incubated with 
secondary antibodies for 1 h at RT, and mounted in Mowiol 
(Sigma). Gel-embedded beads coated with endothelial cells were 
dried on glass slides, rehydrated in PBS containing 100 mM Tris 
pH 8.3, fixed, and blocked, as described above. Staining with 
primary antibodies was performed for 20 h at 4 °C in blocking 
buffer containing 0.1% Triton X-100. Incubation with second-
ary antibodies and mounting were performed as described above. 
Primary antibodies specific for LYVE-1 (ABBIOTEC, rabbit), 
VEGFR-3 (ABBIOTEC, rabbit), podoplanin (ABBIOTEC, rab-
bit), PROX-1 (R&D, goat), neuropilin-1, VEGF-D (GeneTex, 
rabbit), neuropilin-2 (R&D, goat), VEGF-A (R&D, mouse), 
CD31 (Abcam, mouse), and VEGF-C (Abcam, mouse) were 
used. Appropriate secondary antibodies prepared in donkey and 
coupled to Alexa Fluor-647, -488, or -594 were purchased from 
Invitrogen. Alternatively, a Zenon Alexa Fluor 647 rabbit IgG 
labeling kit from Invitrogen was used for fluorescence labeling. 
Fluorescent images were taken using a Zeiss LSM 510 META 
confocal microscope in the Cellular Imaging Facility.41 Each 
image is the result of a maximum intensity projection of six opti-
cal sections (optical slice < 1 μm).
In vitro cell differentiation, isolation, and activation
CD34+ hematopoietic progenitors from cord blood were iso-
lated by immunomagnetic selection (StemCell Technologies 
Inc.) and cultured as previously described.27,28 At 15 to 25 d after 
isolation, the cells were used for isolation of podoplanin+ cells 
or stimulated by addition of recombinant VEGF at 50 ng/mL 
unless stated otherwise. The cell linker dyes PKH2, PKH67 
(Sigma-Aldrich) or CFSE (carboxyfluorescein diacetate succin-
imidyl ester, Invitrogen) were incorporated into precursor cells, 
and cell proliferation and differentiation was monitored by flow 
cytometry (see below).
Analysis of cell phenotype by fluorescence cytometry
Following blockade of Fc receptors (FcR blocking reagent, 
Myltenyi Biotec), cells were labeled with fluorophore con-
jugated antibodies to the following proteins: human CD31-
FITC (BD, mouse), CD34-PerCP (BD, mouse), CD45-Pacific 
Orange (Invitrogen, mouse), CD11b-PE-Cy7 (BD, mouse), 
human neuropilin-1-PE (Miltenyi Biotec, mouse), CD133-APC 
(Miltenyi Biotec, mouse), human VEGFR-1 (Abcam, rabbit), 
VEGFR-2-PE (R&D, goat), VEGFR-3 (ABBIOTEC, rabbit), 
CD11c-Pacific Blue (Biolegend, mouse), CD14-PerCP-Cy5.5 
(Biolegend, mouse), and CD14-APC (BD, mouse). Unlabeled 
antibodies used included anti-podoplanin (ABBIOTEC, rab-
bit followed by a Cy5 goat anti-rabbit or Dylight-488 donkey 
anti-rabbit, both from Jackson Immunoresearch),and mouse 
VE-Cadherin (R&D, goat followed by an Alexa-647 donkey 
anti-goat from Invitrogen). Labeled cells were analyzed using a 
LSRII flow cytometer (BD Biosciences) equipped with a 610/20 
nm filter on the violet detector.
In vitro and in vivo angiogenesis assay
After 15 to 25 d in culture, podoplanin+ cells were isolated 
by immunomagnetic selection (StemCell Technologies Inc.) 
using anti–podoplanin-PE antibody (Biolegend). The cell-
tracing reagent CFSE was incorporated into endothelial cells 
to discriminate and quantify sprouts of blood and lymphatic 
origins. Monolayers of HUVECs and podoplanin+ cells were 
co-cultured on microcarrier beads (2:1, HUVEC: podoplanin+ 
cells) and embedded in a three-dimensional fibrin gel42 over-
laid with normal human dermal fibroblasts using a modified 
procedure.43,44 The sprouting capacity of HUVECs and podo-
planin+ cells in response to VEGF was evaluated by measuring 
the mean cumulated sprout length per bead on 10 spheroids or 
beads.28
Mouse experiments were approved by the cantonal veterinary 
service (Vaud). For the in vivo corneal vascularization assay, 
30,000 podoplanin+ cells were isolated by positive immuno-
magnetic selection (purity > 95%, Stem Cell Technologies) and 
injected in a 5-μL volume into the stromal part of the corneas 
of anesthetized NOD-SCID/IL2Rγnull mice36 using a 35-gauge 
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Oncoimmunology e29080-10
 References
1. Choi I, Lee S, Hong YK. The new era of the lym-
phatic system: no longer secondary to the blood 
vascular system. Cold Spring Harb Perspect Med 
2012; 2:a006445; PMID:22474611; http://dx.doi.
org/10.1101/cshperspect.a006445
2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh 
L. VEGF receptor signalling - in control of vascu-
lar function. Nat Rev Mol Cell Biol 2006; 7:359-
71; PMID:16633338; http://dx.doi.org/10.1038/
nrm1911
3. Zumsteg A, Christofori G. Myeloid cells and lym-
phangiogenesis. Cold Spring Harb Perspect Med 
2012; 2:a006494; PMID:22675661; http://dx.doi.
org/10.1101/cshperspect.a006494
4. Asahara T, Kawamoto A. Endothelial progenitor 
cells for postnatal vasculogenesis. Am J Physiol Cell 
Physiol 2004; 287:C572-9; PMID:15308462; http://
dx.doi.org/10.1152/ajpcell.00330.2003
5. Velazquez OC. Angiogenesis and vasculogenesis: 
inducing the growth of new blood vessels and wound 
healing by stimulation of bone marrow-derived pro-
genitor cell mobilization and homing. J Vasc Surg 
2007; 45(Suppl A):A39-47; PMID:17544023; 
http://dx.doi.org/10.1016/j.jvs.2007.02.068
6. Baluk P, Yao LC, Feng J, Romano T, Jung SS, Schreiter 
JL, Yan L, Shealy DJ, McDonald DM. TNF-alpha 
drives remodeling of blood vessels and lymphatics in 
sustained airway inflammation in mice. J Clin Invest 
2009; 119:2954-64; PMID:19759514
7. Kataru RP, Jung K, Jang C, Yang H, Schwendener 
RA, Baik JE, Han SH, Alitalo K, Koh GY. Critical 
role of CD11b+ macrophages and VEGF in inflam-
matory lymphangiogenesis, antigen clearance, and 
inflammation resolution. Blood 2009; 113:5650-
9; PMID:19346498; http://dx.doi.org/10.1182/
blood-2008-09-176776
8. Kang S, Lee SP, Kim KE, Kim HZ, Mémet S, Koh 
GY. Toll-like receptor 4 in lymphatic endothelial 
cells contributes to LPS-induced lymphangiogenesis 
by chemotactic recruitment of macrophages. Blood 
2009; 113:2605-13; PMID:19098273; http://dx.doi.
org/10.1182/blood-2008-07-166934
9. Hall KL, Volk-Draper LD, Flister MJ, Ran S. New 
model of macrophage acquisition of the lymphatic 
endothelial phenotype. PLoS One 2012; 7:e31794; 
PMID:22396739; http://dx.doi.org/10.1371/jour-
nal.pone.0031794
10. Saaristo A, Tammela T, Farkkilā A, Kärkkäinen M, 
Suominen E, Yla-Herttuala S, Alitalo K. Vascular 
endothelial growth factor-C accelerates diabetic 
wound healing. Am J Pathol 2006; 169:1080-
7; PMID:16936280; http://dx.doi.org/10.2353/
ajpath.2006.051251
11. Takahashi TA, Rebulla P, Armitage S, van 
Beckhoven J, Eichler H, Kekomäki R, Letowska 
M, Wahab F, Moroff G. Multi-laboratory evalua-
tion of procedures for reducing the volume of cord 
blood: influence on cell recoveries. Cytotherapy 
2006; 8:254-64; PMID:16793734; http://dx.doi.
org/10.1080/14653240600735677
12. Religa P, Cao R, Bjorndahl M, Zhou Z, Zhu Z, Cao Y. 
Presence of bone marrow-derived circulating progeni-
tor endothelial cells in the newly formed lymphatic 
vessels. Blood 2005; 106:4184-90; PMID:16141354; 
http://dx.doi.org/10.1182/blood-2005-01-0226
13. Jiang S, Bailey AS, Goldman DC, Swain JR, Wong 
MH, Streeter PR, Fleming WH. Hematopoietic stem 
cells contribute to lymphatic endothelium. PLoS One 
2008; 3:e3812; PMID:19043576; http://dx.doi.
org/10.1371/journal.pone.0003812
14. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener 
R, Rüegg C, Christofori G. Myeloid cells contribute to 
tumor lymphangiogenesis. PLoS One 2009; 4:e7067; 
PMID:19759906; http://dx.doi.org/10.1371/jour-
nal.pone.0007067
15. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi 
K, Shibuya M, Saya H, Suda T. M-CSF inhibition 
selectively targets pathological angiogenesis and 
lymphangiogenesis. J Exp Med 2009; 206:1089-
102; PMID:19398755; http://dx.doi.org/10.1084/
jem.20081605
16. Gordon EJ, Rao S, Pollard JW, Nutt SL, Lang RA, 
Harvey NL. Macrophages define dermal lymphatic 
vessel calibre during development by regulating lym-
phatic endothelial cell proliferation. Development 
2010; 137:3899-910; PMID:20978081; http://
dx.doi.org/10.1242/dev.050021
17. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen 
MJ, Haiko P, Salven P, Alitalo K. Preexisting lym-
phatic endothelium but not endothelial progenitor 
cells are essential for tumor lymphangiogenesis and 
lymphatic metastasis. Cancer Res 2004; 64:3737-40; 
PMID:15172976; http://dx.doi.org/10.1158/0008-
5472.CAN-04-0088
18. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich 
R, Caucig C, Kriehuber E, Nagy K, Alitalo K, 
Kerjaschki D. Tumor-associated macrophages express 
lymphatic endothelial growth factors and are related 
to peritumoral lymphangiogenesis. Am J Pathol 
2002; 161:947-56; PMID:12213723; http://dx.doi.
org/10.1016/S0002-9440(10)64255-1
19. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, 
Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, 
Ankersmit HJ, et al. High VEGFR-3-positive circu-
lating lymphatic/vascular endothelial progenitor cell 
level is associated with poor prognosis in human small 
cell lung cancer. Clin Cancer Res 2009; 15:1741-6; 
PMID:19240177; http://dx.doi.org/10.1158/1078-
0432.CCR-08-1372
20. Kerjaschki D, Huttary N, Raab I, Regele H, 
Bojarski-Nagy K, Bartel G, Kröber SM, Greinix H, 
Rosenmaier A, Karlhofer F, et al. Lymphatic endo-
thelial progenitor cells contribute to de novo lym-
phangiogenesis in human renal transplants. Nat Med 
2006; 12:230-4; PMID:16415878; http://dx.doi.
org/10.1038/nm1340
21. Attout T, Hoerauf A, Dénécé G, Debrah AY, Marfo-
Debrekyei Y, Boussinesq M, Wanji S, Martinez V, 
Mand S, Adjei O, et al. Lymphatic vascularisation and 
involvement of Lyve-1+ macrophages in the human 
onchocerca nodule. PLoS One 2009; 4:e8234; 
PMID:20011036; http://dx.doi.org/10.1371/journal.
pone.0008234
22. El-Chemaly S, Malide D, Zudaire E, Ikeda Y, 
Weinberg BA, Pacheco-Rodriguez G, Rosas IO, 
Aparicio M, Ren P, MacDonald SD, et al. Abnormal 
lymphangiogenesis in idiopathic pulmonary fibrosis 
with insights into cellular and molecular mecha-
nisms. Proc Natl Acad Sci U S A 2009; 106:3958-
63; PMID:19237567; http://dx.doi.org/10.1073/
pnas.0813368106
23. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio 
A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, 
Yoder MC. Identification of a novel hierarchy of 
endothelial progenitor cells using human peripheral 
and umbilical cord blood. Blood 2004; 104:2752-
60; PMID:15226175; http://dx.doi.org/10.1182/
blood-2004-04-1396
24. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii 
S. VEGFR-3 and CD133 identify a population of 
CD34+ lymphatic/vascular endothelial precursor 
cells. Blood 2003; 101:168-72; PMID:12393704; 
http://dx.doi.org/10.1182/blood-2002-03-0755
nanofil injection kit (WPI). Blood and lymphatic vessels were 
detectable in the mouse cornea from days 15 and 22 post-injection, 
respectively. Mice were euthanized at 30 d post-injection and iso-
lated eyes were fixed in 4% paraformaldehyde, cryoprotected in 
a 30% sucrose solution and embedded in Yazulla medium (30% 
egg albumin, 3% gelatin). In contrast to blood vessels, lymphat-
ics are transparent and vascularization was assessed by immu-
nostaining of 10-µm sagittal sections with antibodies specific for 
CD31 and LYVE-1 using a Zeiss Axio Imager M1 fluorescent 
microscope. The retina was used as a positive control for CD31 
staining.
Reagents
All chemicals were from Sigma-Aldrich unless indicated oth-
erwise. Human recombinant cytokines were purchased from 
PeproTech and R&D Systems.
Statistical analyses
The Student t test statistical analyses were performed using 
GraphPad Prism version 4.00 for Windows (GraphPad Software).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
This work was supported grants from Oncosuisse (M.-A.D. 
project 02069-04-2007), the Swiss National Foundation (M.-A.D. 
project 310030-120473 and J.-F.D. project CR32I3_135073), 
and the Medic Foundation (M.-A.D. Project). We thank Pr T. 
Petrova (University of Lausanne) for providing antibodies spe-
cific for Prox1 and VE-Cadherin.
Authorship contributions
E.F. designed the study, performed research, and analyzed 
and interpreted the data. S.B. and R.T. performed research and 
analyzed the data. L.H. and G.C. interpreted the data and wrote 
the manuscript. J.-F.D. and A.I.T. managed patients, contrib-
uted human specimens, and interpreted data. M.-A.D. designed 
and performed research, interpreted the data, and wrote the 
manuscript.
Supplemental Materials
Supplemental materials may be found here: 
www.landesbioscience.com/journa ls /oncoimmunology/
article/29080/
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
www.landesbioscience.com Oncoimmunology e29080-11
25. Romagnani P, Annunziato F, Liotta F, Lazzeri E, 
Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni 
L, Scheffold A, et al. CD14+CD34low cells with stem 
cell phenotypic and functional features are the major 
source of circulating endothelial progenitors. Circ Res 
2005; 97:314-22; PMID:16020753; http://dx.doi.
org/10.1161/01.RES.0000177670.72216.9b
26. Hildbrand P, Cirulli V, Prinsen RC, Smith KA, 
Torbett BE, Salomon DR, Crisa L. The role of 
angiopoietins in the development of endothelial 
cells from cord blood CD34+ progenitors. Blood 
2004; 104:2010-9; PMID:15213103; http://dx.doi.
org/10.1182/blood-2003-12-4219
27. Niu XL, Peters KG, Kontos CD. Deletion of the 
carboxyl terminus of Tie2 enhances kinase activity, 
signaling, and function. Evidence for an autoinhibi-
tory mechanism. J Biol Chem 2002; 277:31768-73; 
PMID:12082108; http://dx.doi.org/10.1074/jbc.
M203995200
28. Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, 
Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, 
Alghisi GC, et al. Proangiogenic factor PlGF pro-
grams CD11b(+) myelomonocytes in breast cancer 
during differentiation of their hematopoietic progeni-
tors. Cancer Res 2011; 71:3781-91; PMID:21507936; 
http://dx.doi.org/10.1158/0008-5472.CAN-10-3684
29. Yoder MC. Human endothelial progenitor cells. 
Cold Spring Harb Perspect Med 2012; 2:a006692; 
PMID:22762017; http://dx.doi.org/10.1101/cshper-
spect.a006692
30. Peters R, Leyvraz S, Faes-Van’t Hull E, Jaunin P, 
Gerber S, Rollini P. Long-term ex vivo expansion 
of human fetal liver primitive haematopoietic pro-
genitor cells in stroma-free cultures. Br J Haematol 
2002; 119:792-802; PMID:12437662; http://dx.doi.
org/10.1046/j.1365-2141.2002.03873.x
31. Hong YK, Harvey N, Noh YH, Schacht V, Hirakawa 
S, Detmar M, Oliver G. Prox1 is a master control gene 
in the program specifying lymphatic endothelial cell 
fate. Dev Dyn 2002; 225:351-7; PMID:12412020; 
http://dx.doi.org/10.1002/dvdy.10163
32. Johnson NC, Dillard ME, Baluk P, McDonald DM, 
Harvey NL, Frase SL, Oliver G. Lymphatic endo-
thelial cell identity is reversible and its maintenance 
requires Prox1 activity. Genes Dev 2008; 22:3282-
91; PMID:19056883; http://dx.doi.org/10.1101/
gad.1727208
33. Oliver G, Detmar M. The rediscovery of the lymphatic 
system: old and new insights into the development 
and biological function of the lymphatic vascula-
ture. Genes Dev 2002; 16:773-83; PMID:11937485; 
http://dx.doi.org/10.1101/gad.975002
34. Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, 
Virtanen I, Ferrell RE, Finegold DN, Kerjaschki 
D, Ylä-Herttuala S, Alitalo K. Lymphatic endothe-
lial reprogramming of vascular endothelial cells by 
the Prox-1 homeobox transcription factor. EMBO J 
2002; 21:4593-9; PMID:12198161; http://dx.doi.
org/10.1093/emboj/cdf470
35. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld 
G, Gunn MD, Jackson DG, Oliver G. An essen-
tial role for Prox1 in the induction of the lymphatic 
endothelial cell phenotype. EMBO J 2002; 21:1505-
13; PMID:11927535; http://dx.doi.org/10.1093/
emboj/21.7.1505
36. Gimbrone MA Jr., Cotran RS, Leapman SB, Folkman 
J. Tumor growth and neovascularization: an experi-
mental model using the rabbit cornea. J Natl Cancer 
Inst 1974; 52:413-27; PMID:4816003
37. Oliver G, Srinivasan RS. Endothelial cell plas-
ticity: how to become and remain a lymphatic 
endothelial cell. Development 2010; 137:363-72; 
PMID:20081185; http://dx.doi.org/10.1242/
dev.035360
38. Alitalo A, Detmar M. Interaction of tumor cells and 
lymphatic vessels in cancer progression. Oncogene 
2012; 31:4499-508; PMID:22179834; http://dx.doi.
org/10.1038/onc.2011.602
39. Christiansen A, Detmar M. Lymphangiogenesis 
and cancer. Genes Cancer 2011; 2:1146-
58; PMID:22866206; http://dx.doi.
org/10.1177/1947601911423028
40. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, 
Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, 
et al. Preparing the “soil”: the primary tumor induces 
vasculature reorganization in the sentinel lymph node 
before the arrival of metastatic cancer cells. Cancer 
Res 2006; 66:10365-76; PMID:17062557; http://
dx.doi.org/10.1158/0008-5472.CAN-06-2977
41. Ibberson M, Bron S, Guex N, Faes-van’t Hull E, 
Ifticene-Treboux A, Henry L, Lehr HA, Delaloye 
JF, Coukos G, Xenarios I, et al. TIE-2 and VEGFR 
kinase activities drive immunosuppressive func-
tion of TIE-2-expressing monocytes in human 
breast tumors. Clin Cancer Res 2013; 19:3439-49; 
PMID:23649001; http://dx.doi.org/10.1158/1078-
0432.CCR-12-3181
42. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch 
U, Risau W. Angiopoietin-1 induces sprout-
ing angiogenesis in vitro. Curr Biol 1998; 8:529-
32; PMID:9560344; http://dx.doi.org/10.1016/
S0960-9822(98)70205-2
43. Nehls V, Drenckhahn D. A novel, microcarrier-based 
in vitro assay for rapid and reliable quantification of 
three-dimensional cell migration and angiogenesis. 
Microvasc Res 1995; 50:311-22; PMID:8583947; 
http://dx.doi.org/10.1006/mvre.1995.1061
44. Nakatsu MN, Davis J, Hughes CC. Optimized fibrin 
gel bead assay for the study of angiogenesis. J Vis Exp 
2007; 186; PMID:18978935
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
